Cerevel Therapeutics Holdings IncNASDAQ:CERE
- LAST PRICE42.7200
- TODAY'S CHANGE (%)-0.0300 (-0.0702%)
- Bid / Lots42.7200/ 2
- Ask / Lots42.7300/ 4
- Open / Previous Close42.5700 / 42.7500
- Day Range
- 52 Week Range
- Volume514,469
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CERE |
|---|---|---|
| 09:32 ET | 3613 | 42.7 |
| 09:34 ET | 2300 | 42.71 |
| 09:36 ET | 1000 | 42.71 |
| 09:38 ET | 700 | 42.68 |
| 09:39 ET | 4300 | 42.76 |
| 09:41 ET | 31020 | 42.75 |
| 09:45 ET | 1000 | 42.78 |
| 09:48 ET | 3368 | 42.745 |
| 09:50 ET | 13749 | 42.73 |
| 09:52 ET | 1300 | 42.745 |
| 09:54 ET | 2040 | 42.75 |
| 09:56 ET | 10763 | 42.74 |
| 09:57 ET | 1120 | 42.75 |
| 09:59 ET | 500 | 42.75 |
| 10:01 ET | 900 | 42.75 |
| 10:03 ET | 1300 | 42.74 |
| 10:06 ET | 2694 | 42.735 |
| 10:08 ET | 800 | 42.745 |
| 10:10 ET | 200 | 42.75 |
| 10:12 ET | 40500 | 42.745 |
| 10:14 ET | 4353 | 42.745 |
| 10:15 ET | 1347 | 42.75 |
| 10:17 ET | 12185 | 42.745 |
| 10:19 ET | 1641 | 42.75 |
| 10:21 ET | 500 | 42.75 |
| 10:24 ET | 1700 | 42.745 |
| 10:26 ET | 500 | 42.745 |
| 10:28 ET | 2205 | 42.745 |
| 10:30 ET | 500 | 42.745 |
| 10:32 ET | 2170 | 42.725 |
| 10:33 ET | 900 | 42.71 |
| 10:35 ET | 680 | 42.705 |
| 10:37 ET | 200 | 42.7 |
| 10:39 ET | 617 | 42.705 |
| 10:44 ET | 971 | 42.705 |
| 10:46 ET | 494 | 42.705 |
| 10:48 ET | 400 | 42.705 |
| 10:50 ET | 300 | 42.705 |
| 10:51 ET | 800 | 42.71 |
| 10:53 ET | 400 | 42.705 |
| 10:55 ET | 300 | 42.71 |
| 10:57 ET | 300 | 42.705 |
| 11:00 ET | 1500 | 42.72 |
| 11:02 ET | 2646 | 42.725 |
| 11:04 ET | 1700 | 42.725 |
| 11:06 ET | 700 | 42.72 |
| 11:08 ET | 6563 | 42.64 |
| 11:09 ET | 2500 | 42.65 |
| 11:11 ET | 200 | 42.665 |
| 11:13 ET | 300 | 42.665 |
| 11:15 ET | 700 | 42.665 |
| 11:18 ET | 200 | 42.665 |
| 11:20 ET | 3100 | 42.695 |
| 11:22 ET | 933 | 42.715 |
| 11:24 ET | 22960 | 42.715 |
| 11:26 ET | 24484 | 42.705 |
| 11:27 ET | 18285 | 42.705 |
| 11:29 ET | 5631 | 42.665 |
| 11:31 ET | 300 | 42.665 |
| 11:33 ET | 1621 | 42.665 |
| 11:36 ET | 780 | 42.6648 |
| 11:38 ET | 1200 | 42.665 |
| 11:40 ET | 1600 | 42.665 |
| 11:42 ET | 22810 | 42.655 |
| 11:44 ET | 5334 | 42.65 |
| 11:45 ET | 901 | 42.655 |
| 11:47 ET | 5013 | 42.655 |
| 11:49 ET | 8043 | 42.65 |
| 11:51 ET | 22506 | 42.625 |
| 11:54 ET | 400 | 42.625 |
| 11:56 ET | 900 | 42.625 |
| 11:58 ET | 1495 | 42.64 |
| 12:02 ET | 2083 | 42.645 |
| 12:03 ET | 200 | 42.65 |
| 12:05 ET | 200 | 42.65 |
| 12:07 ET | 300 | 42.65 |
| 12:09 ET | 1900 | 42.64 |
| 12:12 ET | 796 | 42.65 |
| 12:14 ET | 800 | 42.645 |
| 12:16 ET | 100 | 42.65 |
| 12:18 ET | 700 | 42.645 |
| 12:20 ET | 8500 | 42.64 |
| 12:21 ET | 2389 | 42.65 |
| 12:23 ET | 700 | 42.645 |
| 12:25 ET | 5445 | 42.655 |
| 12:27 ET | 800 | 42.655 |
| 12:30 ET | 2174 | 42.655 |
| 12:32 ET | 3550 | 42.655 |
| 12:34 ET | 4049 | 42.645 |
| 12:36 ET | 2377 | 42.675 |
| 12:38 ET | 1535 | 42.67 |
| 12:39 ET | 1300 | 42.655 |
| 12:41 ET | 800 | 42.665 |
| 12:43 ET | 16150 | 42.675 |
| 12:45 ET | 200 | 42.675 |
| 12:48 ET | 1100 | 42.675 |
| 12:50 ET | 3280 | 42.6701 |
| 12:52 ET | 2411 | 42.675 |
| 12:54 ET | 200 | 42.675 |
| 12:56 ET | 8699 | 42.725 |
| 12:57 ET | 5055 | 42.74 |
| 12:59 ET | 1456 | 42.73 |
| 01:03 ET | 500 | 42.735 |
| 01:06 ET | 2761 | 42.74 |
| 01:08 ET | 100 | 42.74 |
| 01:10 ET | 2010 | 42.735 |
| 01:12 ET | 19647 | 42.72 |
| 01:14 ET | 2400 | 42.725 |
| 01:15 ET | 100 | 42.73 |
| 01:17 ET | 5951 | 42.715 |
| 01:19 ET | 200 | 42.72 |
Today
Apr 18, 2024
DJ AbbVie's Bet on a Neuroscience Drug Maker Just Got Better -- Heard on the Street -- WSJ, from 12:17PM ET on Thursday Apr 18, 2024 by Dow Jones
12:17PM ET on Thursday Apr 18, 2024 by Dow JonesCerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease, from 6:30AM ET on Thursday Apr 18, 2024 by Dow Jones
6:30AM ET on Thursday Apr 18, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cerevel Therapeutics Holdings Inc | 7.8B | -16.1x | --- |
Viking Therapeutics Inc | 8.3B | -83.6x | --- |
Vaxcyte Inc | 6.6B | -14.9x | --- |
Cytokinetics Inc | 6.5B | -11.3x | --- |
Revolution Medicines Inc | 6.3B | -9.9x | --- |
Immunitybio Inc | 6.1B | -7.3x | --- |
Company Information
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.
Contact Information
- Headquarters
- 222 Jacobs Street, Suite 200CAMBRIDGE, MA, United States 02141
- Phone
- 212-284-2300
- Fax
- 302-636-5454
Executives
- Chairperson of the Board of Directors
- N. Coles
- President, Chief Executive Officer, Member of the Board
- Ronald Renaud
- Chief Financial Officer
- Susan Altschuller
- Chief Human Resources Officer
- Kenneth Dipietro
- Senior Vice President - Finance, Chief Accounting Officer
- Mark Bodenrader
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.8B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 181.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.48 |
EPS | $-2.66 |
Book Value | $3.71 |
P/E Ratio | -16.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
